Testing effectiveness (Phase 2)Ended earlyNCT04488003
What this trial is testing
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Who this might be right for
Advanced Solid TumorBRAF Gene MutationBRAF Gene Alteration+6 more
BioMed Valley Discoveries, Inc 104